Our lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to chemotherapy. We are interested in developing therapies that can adapt to the evolution of chemotherapy resistance over time. We also use drug repurposing approaches to specifically target chemotherapy-resistant ovarian cancers and to improve the therapeutic benefit of oncolytic viral therapies.
Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov (2018) 8(3):304-319. PMID: 29196464
Beta3 integrin inhibition reduces the inflammatory toxicities induced by oncolytic adenovirus without compromising anticancer activity. Cancer Res (2015) 75(14):2811-21. PMID: 25977332
Chemotherapy Response Score (CRS): Development and validation of a system to quantify histopathological response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma. J Clin Oncol (2015) 33(22):2457-63. PMID: 26124480
Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Mol Oncol (2014) 9(4):791-805. PMID: 25560085
High grade serous cancer (HGSC) is the most common subtype of ovarian cancer. It is initially very responsive to platinum and taxane chemotherapy but more than 70% patients develop chemotherapy resistance and the disease becomes incurable.
Circumventing resistance is therefore a major unmet clinical need. The Lockley lab has created a panel of chemotherapy resistant HGSC cell lines and are using these to identify novel treatments for chemoresistant disease.
We aim to improve the utility of oncolytic viruses, whose clinical potential has so far been limited by inflammatory toxicity induced when they are administered systemically.
We showed for the first time that these inflammatory toxicities can be reduced by inhibition of β3 integrin, a cell surface signalling and adhesion protein, without compromising anticancer activity.
We now aim to further improve viral anti-cancer efficacy through combination with immune-modulatory therapies.
I set up and continue to lead the Barts Gynae Tissue Bank, This repository of tissue kindly donated by Barts patients is widely used by scientists at the BCI and elsewhere. It is the basis of the ERC funded CanBuild project lead by Prof Balkwill, which is creating innovative and accurate 3D models of the human omentum in high grade serous cancer.
I am Medical Adviser for this project.
Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: Signpost study Chandrasekaran D, Sobocan M, Blyuss O et al. Cancers (2021) 13(7)
LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations Lakatos E, Hockings H, Mossner M et al. iScience (2021) 24(7)
Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’ Lockley M, Stoneham S, Shamash J et al. European Journal of Cancer (2021) 152(7) 255-256
A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion Malacrida B, Nichols S, Maniati E et al. iScience (2021) 24(7)
Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer Silva VL, Saxena J, Nicolini F et al. Cell Death and Disease (2021) 12(7)
Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448 (Gynecologic Oncology (2019) 154(2) (441–448), (S0090825819311813), (10.1016/j.ygyno.2019.04.679)) Cohen PA, Powell A, Böhm S et al. Gynecologic Oncology (2021) 161(7) 328-329
Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial Morgan RD, McNeish IA, Cook AD et al. The Lancet Oncology (2021) 22(7) 277-288
Identification of a novel regulator of FANCD2 mediated DNA Repair Tse WY, Maniati E, Wang J et al. (2021) (10) 9200
The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG) Shamash J, Ansell W, Alifrangis C et al. British Journal of Cancer (2021) 124(7) 368-374
Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study Oxley SG, Achampong YA, Sambandan N et al. Acta Obstetricia et Gynecologica Scandinavica (2021) (7)For additional publications, please click here
Postdoctoral Researchers in this group
Dr Joseph Hoare
Clinical Research Fellows
Dr Helen Hockings, Dr Georgina Wood
Dr Francesco Nicolini
Education and qualifications